BD Medical Unveils Over a Dozen Global and China Premieres at the 6th CIIE, Reinforcing Commitment to Local Innovation and High-Quality Healthcare Development

Committed to Innovation and "Resonating with the Frequency" of China's Medical Device Industry

ShanghaiNovember 5, 2023/PR Newswire/ --Today, the 6th China International Import Expo (hereinafter referred to as "CIIE") officially opened at the National Exhibition and Convention Center.Global Medical Technology Giant BDIn"Resolve · Excellence" Debuts at This Year’s CIIE, with the Theme of Innovating Practices to Safeguard Patient Health in All Scenarios for Future Well-being.

This year marks the fourth consecutive year that BD has participated in the CIIE. Centered on the four themes of "Frontier Life Science Exploration, Clinical Testing and Health Management, Innovative Ecosystem for Patient Surgical Procedures, and Precision Oncology Screening and Treatment," BD will comprehensively showcase its innovative medical technology achievements and latest product solutions, further strengthening its commitment to align with the high-quality development of China's healthcare industry.

Since its global founding in 1897, BD has been leading the medical industry with innovations and developing numerous well-known medical technologies. Guided by the commitment to "start with patient needs," since entering China in 1994, BD has delivered hundreds of thousands of innovative products and is dedicated to accelerating the introduction of more advanced medical devices to improve accessibility for local patients.

In response to this,Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater China, stated:"The annual China International Import Expo (CIIE) demonstrates a powerful spillover effect, boosting high-quality economic development in China and promoting open cooperation and exchange in the medical device industry. Leveraging the CIIE’s platform advantages of openness, innovation, cooperation, and win-win outcomes, BD will continue to focus on cutting-edge technological innovation and deepen its 'symbiotic' relationship with the high-quality development of China's healthcare industry, committing to bring more new products, technologies, and services to China."

Heavyweight Product Makes Debut, Innovating to Benefit More Patients

In recent years, the development of China's medical device industry has consistently revolved around the keyword "innovation," which is also a long-term philosophy upheld by BD. This year, BD showcased more than ten global and China-first innovative products, along with nearly a hundred star products at its booth. These include the first domestically produced, cost-effective clinical flow cytometer, Matecyte™, launched in collaboration with local partners; the ultra-high-throughput single-cell multi-omics platform BD Rhapsody™ HT Xpress; the first pre-processing system for single-cell intelligent sequencers independently developed and manufactured in partnership with a local high-tech enterprise; the flow fluorescent reagent BD Horizon™ Real series, leading the second wave of dye innovation; the adjustable bend transjugular intrahepatic puncture device Liverty™; the peripheral-inserted midline catheter PowerMe®; the implantable high-pressure infusion port Clearvue™; the M.R.I™ Ultra Low-Profile Implantable Port for arm implantation; the GlidePath™ central venous catheter and kit for hemodialysis; the breast tissue marker UltraCor™ Twirl™ Breast Tissue Marker; the first external female urine collection stick PUREWICK®, designed to address bedridden female urinary management while improving care quality and reducing catheter-associated urinary tract infections; the disposable laparoscopic catheter Avitene™ Dispenser; and the wearable auto-injector BD Libertas™ Wearable Injector. Leveraging the platform advantages of the 6th CIIE, these groundbreaking innovations and solutions are being introduced to the Chinese market to benefit more patients across China.

Among them:

Matecyte™ Clinical Flow CytometerBD has launched its first domestically produced, high cost-effective, and portable clinical flow cytometer. With simple operation and low installation environment requirements, it can assist extensive municipal-level hospitals in conducting routine flow cytometry tests in fever clinics, hematology, infectious diseases, and critical care departments, enabling patients to access tiered medical treatment without leaving their city. This globally premiered product will showcase China's innovative strength in the field of medical technology to the world.

BD Liverty™ Adjustable Bend Puncture KitIt is the world's first adjustable bend rigid cannula, developed by a Chinese team and launched simultaneously in China and internationally. With precise and controllable in vivo bending technology, it improves the most challenging step of intrahepatic portal vein puncture during surgery, making the procedure safer and more efficient.

PowerMe™ Midline Catheter via Peripheral InsertionAnother notable innovative product from BD Medical, developed and manufactured with the collaboration of local Chinese and global efforts. This new "game-changing" infusion device, designed to protect patients' blood vessels, will make its global debut at the CIIE. Its patented one-piece single-wing needle structure combined with high-pressure injection capability marks another significant milestone in the development of clinical vascular access.

Leverage the Platform Effect of the CIIE to Promote Industrial Exchange and Cooperation

In addition to introducing innovative products from its global headquarters, BD continues to increase its efforts in fostering local innovation in China. In July this year, BD Greater China Innovation Center was unveiled in Hangzhou, joining the Innovation Design and Multi-functional R&D Center in Shanghai and the Engineering Lab R&D Center in Suzhou to further enhance and empower BD's comprehensive innovation capabilities with multi-party partners. In terms of localization innovation strategy, BD optimizes product functions and accelerates product implementation based on the needs of the Chinese market, while also conducting local innovative development according to the needs of Chinese patients, in order to better meet local market demands.

BD has always been driven by technological innovation, leading the development concept of the industry's future direction, and practicing the strategic concept of "Rooting in China, Serving China." It actively builds a local innovation ecosystem. At the fourth, fifth, and this sixth CIIE, BD has served as the chairman unit of the Medical Device Professional Committee of the CIIE for three consecutive years. Since 2021, BD has taken the lead in assisting the medical exhibition area of the CIIE to establish an innovation incubation zone, gathering government, investment, and industry parties to help global medical technology innovation companies take root in China, jointly drawing a new blueprint for innovation-driven high-quality development in the healthcare industry.

At this year's CIIE, BD Medical will hold several new product launches, strategic cooperation events, and signing ceremonies, working hand-in-hand with industry peers to promote industrial growth and enhance cooperation and exchange. These include products and collaborations in the bioscience field such as FACSLyric, S8, HT Xpress, MateCyte, the partnership with Rapid Medical, and BD Medical’s Single-Cell Automated Library Preparation Workstation; at the corporate level, a Memorandum of Strategic Cooperation with Shanghai Waigaoqiao Group.；StatLock e-commerce signing in the drug infusion solutions field, Sinopharm Group dealer signing; cooperation signing with Xiehe Medical in the pharmaceutical systems field, and annual cooperation signings with major hospitals, among other signing activities.

Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater ChinaStated: "With the spillover effects and communication platform of the CIIE, BD will continue to increase its investment in China and actively integrate into the new wave of shared development opportunities in the Chinese economy. We have deeply felt the new opportunities brought by the openness of the Chinese market for the development of foreign enterprises in China. We hope that through the innovation and cooperation exchange platform of the CIIE, we can further accelerate the implementation of innovative products based on the needs of the Chinese market, while empowering more partners to promote the innovative development of medical technology, achieve universal access to health as soon as possible, and contribute to the advancement of Healthy China."